Rapamycin-resistant T cells and therapeutic uses thereof
AssigneesThe United States of America as represented by the Secretary of the Deparment of Health and Human Services, The Trustees of the University of Pennsylvania
InventorsDaniel H. Fowler, Unsu Jung, Ronald E. Gress, Bruce Levine, Carl June
Life of this patent
Estimating the term…
Abstract
Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.
Claims7
A method for treating a patient suffering from or susceptible to cancer, comprising administering allogeneic Th2 cells wherein said allogeneic Th2 cells are rapamycin resistant TH2 cells that are therapeutically effective and wherein said Th2 cells are selected from T cells cultured in vitro in (i) at least about 0.1 μM rapamycin or a rapamycin derivative and (ii) IL-4.
Dependencies are inferred from the claim text.